|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/28/12 Ziopharm Oncology Inc 10-Q/A 6/30/12 50:3.1M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q/A Amendment to Quarterly Report HTML 29K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 18K
32: R1 Document and Entity Information HTML 37K
23: R2 Balance Sheets HTML 112K
30: R3 Balance Sheets (Parenthetical) HTML 39K
34: R4 Statements Of Operations HTML 67K
46: R5 Statement Of Stockholders' Equity HTML 66K
24: R6 Statement Of Stockholders' Equity (Parenthetical) HTML 18K
29: R7 Statements of Cash Flows HTML 142K
21: R8 Business HTML 26K
15: R9 Summary of Significant Accounting Policies HTML 19K
47: R10 Collaborations and Alliances HTML 21K
36: R11 Fair Value Measurements HTML 38K
35: R12 Net Loss per Share HTML 23K
40: R13 Related Party Transactions HTML 22K
41: R14 Commitments and Contingencies HTML 53K
39: R15 Warrants HTML 52K
42: R16 Common Stock HTML 19K
31: R17 Stock-Based Compensation HTML 48K
33: R18 Fair Value Measurements (Tables) HTML 27K
38: R19 Net Loss per Share (Tables) HTML 22K
50: R20 Warrants (Tables) HTML 42K
44: R21 Stock-Based Compensation (Tables) HTML 52K
26: R22 Business - Additional Information (Detail) HTML 23K
37: R23 Collaborations and Alliances - Additional HTML 24K
Information (Detail)
28: R24 Assets and Liabilities Measured at Fair Value on HTML 26K
Recurring Basis (Detail)
13: R25 Potential Dilutive Shares Excluded from HTML 26K
Computation of Diluted Net Loss Per Share (Detail)
45: R26 Related Party Transactions - Additional HTML 28K
Information (Detail)
48: R27 Commitments and Contingencies - Additional HTML 121K
Information (Detail)
18: R28 Number of Warrants Outstanding (Detail) HTML 21K
17: R29 Warrants - Additional Information (Detail) HTML 74K
19: R30 Assumptions Used In Binomial Valuation Model and HTML 25K
Black-Scholes Valuation Model (Detail)
20: R31 Warrant Exercise (Detail) HTML 32K
22: R32 Common Stock - Additional Information (Detail) HTML 34K
11: R33 Stock-Based Compensation Expense on All Employee HTML 23K
and Non-Employee Awards (Detail)
43: R34 Stock-Based Compensation - Additional Information HTML 31K
(Detail)
25: R35 Fair Value of Stock Options Assumptions Using HTML 34K
Black-Scholes Option Valuation Model (Detail)
27: R36 Stock Option Activity Under Stock Option Plan HTML 83K
(Detail)
14: R37 Summary of Unvested Restricted Stock (Detail) HTML 46K
49: XML IDEA XML File -- Filing Summary XML 74K
16: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 392K
5: EX-101.INS XBRL Instance -- ziop-20120630 XML 731K
7: EX-101.CAL XBRL Calculations -- ziop-20120630_cal XML 109K
8: EX-101.DEF XBRL Definitions -- ziop-20120630_def XML 650K
9: EX-101.LAB XBRL Labels -- ziop-20120630_lab XML 966K
10: EX-101.PRE XBRL Presentations -- ziop-20120630_pre XML 726K
6: EX-101.SCH XBRL Schema -- ziop-20120630 XSD 147K
12: ZIP XBRL Zipped Folder -- 0001144204-12-048414-xbrl Zip 101K
EXHIBIT 32.1
CERTIFICATION
In connection with the Quarterly Report on Form 10-Q of ZIOPHARM Oncology, Inc. (the “Company”) for the period ended June 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we Jonathan Lewis, the Principal Executive Officer of the Company and Jason A. Amello, the Principal Financial and Accounting Officer of the Company, hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to our knowledge:
| (1) | the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and |
| (2) | the information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: August 28, 2012
| /s/ Jonathan Lewis |
|
Jonathan Lewis, M.D., Ph.D. Chief Executive Officer |
| (Principal Executive Officer) |
Dated: August 28, 2012
| /s/ Jason A. Amello |
|
Executive Vice President and Chief Financial Officer |
| (Principal Financial and Accounting Officer) |
C:
| This ‘10-Q/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/28/12 | |||
| For Period end: | 6/30/12 | 10-Q | ||
| List all Filings | ||||